Gene clues could personalize Crohn's treatment
NCT ID NCT07263464
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 818 people with Crohn's disease to see if variations in the TNFSF4 gene are linked to the disease and how well patients respond to the drug ustekinumab. Researchers analyzed blood samples to find genetic patterns. The goal is to better understand why some patients benefit more from treatment than others.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which Crohn's patients will respond best to ustekinumab, leading to more personalized treatment.
- What could go wrong
- This is an observational study, not a treatment trial. It looks at genetic links, so it won't directly test a new therapy. Results may not change practice immediately.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (CROHN'S DISEASE AND ULCERATIVE COLITIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.